Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle
0301 basic medicine
QR Microbiology
Hepacivirus
R Medicine (General)
Viral Nonstructural Proteins
Virus Internalization
Antiviral Agents
3. Good health
03 medical and health sciences
Cell Line, Tumor
Humans
QR180 Immunology
QR355 Virology
Silymarin
DOI:
10.1002/hep.23587
Publication Date:
2010-03-29T20:17:30Z
AUTHORS (17)
ABSTRACT
Silymarin, an extract from milk thistle (
Silybum marianum
), and its purified flavonolignans have been recently shown to inhibit hepatitis C virus (HCV) infection, both
in vitro
and
in vivo
. In the current study, we further characterized silymarin's antiviral actions. Silymarin had antiviral effects against hepatitis C virus cell culture (HCVcc) infection that included inhibition of virus entry, RNA and protein expression, and infectious virus production. Silymarin did not block HCVcc binding to cells but inhibited the entry of several viral pseudoparticles (pp), and fusion of HCVpp with liposomes. Silymarin but not silibinin inhibited genotype 2a NS5B RNA-dependent RNA polymerase (RdRp) activity at concentrations 5 to 10 times higher than required for anti-HCVcc effects. Furthermore, silymarin had inefficient activity on the genotype 1b BK and four 1b RDRPs derived from HCV-infected patients. Moreover, silymarin did not inhibit HCV replication in five independent genotype 1a, 1b, and 2a replicon cell lines that did not produce infectious virus. Silymarin inhibited microsomal triglyceride transfer protein activity, apolipoprotein B secretion, and infectious virion production into culture supernatants. Silymarin also blocked cell-to-cell spread of virus.
Conclusion:
Although inhibition of
in vitro
NS5B polymerase activity is demonstrable, the mechanisms of silymarin's antiviral action appear to include blocking of virus entry and transmission, possibly by targeting the host cell. Hepatology 2010
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (43)
CITATIONS (182)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....